Brand and Other Names:Lexiva
- Classes: HIV, Protease Inhibitors
Dosing & Uses
Dosage Forms & Strengths
- 1400 mg PO q12hr (without ritonavir)
- 1400 mg PO qDay (with ritonavir 100-200 mg qDay)
- 700 mg PO q12hr (with ritonavir 100 mg q12hr)
Protease inhibitor-experienced patients
- 700 mg PO q12hr (with ritonavir 100 mg q12hr)
Coadministration with efavirenz
- 700 mg PO q12hr (with ritonavir 100 mg q12hr) plus 600 mg efavirenz qDay, or
- 1400 mg PO qDay (with ritonavir 300 mg qDay) plus 600 mg efavirenz qDay
Combination with maraviroc
- 700 mg PO q12hr (with ritonavir 100 mg q12hr) plus maraviroc 150 mg PO q12hr
Mild (Child-Pugh 5-6): 700 mg PO q12hr without ritonavir (therapy-naive); OR 700 mg q12hr with ritonavir 100 mg qDay (therapy-naive or protease inhibitor-experienced)
Moderate (Child-Pugh 7-9): 700 mg PO q12hr (therapy-naive) without ritonavir; OR 450 mg q12hr with ritonavir 100 mg qDay (therapy-naive or protease inhibitor-experienced)
Severe (Child-Pugh 10-15): 350 mg PO q12hr without ritonavir (therapy-naive); OR 300 mg q12hr with ritonavir 100 mg qD (therapy-naive or protease-inhibitor experienced)
Tablet: Take with meals if boosted with ritonavir; take without regard to meals if not boosted with ritonavir
Oral suspension: Adults should take without food
Dosage Forms & Strengths
HIV Infection (Protease Inhibitor Naive Patients)
<4 weeks: Safety and efficacy not established
Indicated for protease inhibitor-naive pediatric patients aged 4 weeks or older, and for protease inhibitor-experienced children aged 6 months or older
For infants, use only in those born at 38 weeks' gestation or greater and who have attained a postnatal age of 28 days
11 to <15 kg: 30 mg/kg PO q12hr plus ritonavir 3 mg/kg q12hr
15 kg to <20 kg: 23 mg/kg PO q12hr plus ritonavir 3 mg/kg q12hr
≥20 kg: 18 mg/kg PO q12hr plus ritonavir 3 mg/kg q12hr
NOTE: When dosing with ritonavir, do not exceed adult dose of 700 mg/ritonavir 100 mg q12hr
Alternatively, protease inhibitor-naive children aged 2 yr or older may be administered 30 mg/kg PO q12hr (without ritonavir)
- <2 years: Not recommended without ritonavir
- >2 years and <47 kg: 30 mg/kg/dose PO q12hr; not to exceed 1400 mg PO q12hr
- >2 years and ≥47 kg: 1400 mg PO q12hr
HIV Infection (Protease Inhibitor Experienced Patients)
- Not recommended
- <11 kg: 45 mg/kg/dose PO q12hr; not to exceed 700 mg fosamprenavir/100 mg ritonavir PO q12hr
- 11-15 kg: 30 mg/kg/dose PO q12hr plus 3 mg/kg/dose ritonavir PO q12hr; not to exceed 700 mg fosamprenavir/100 mg ritonavir PO q12hr
- 15 to <20 kg: 23 mg/kg/dose PO q12hr plus 3 mg/kg/dose ritonavir PO q12hr; not to exceed 700 mg fosamprenavir/100 mg ritonavir PO q12hr
- ≥20 kg: 18 mg/kg/dose PO q12hr plus 3 mg/kg/dose ritonavir PO q12hr; not to exceed 700 mg fosamprenavir/100 mg ritonavir PO q12hr
Children should take oral suspension with food except:
≥47 kg: May use adult dosage with tabs (without ritonavir)
≥39 kg: May use adult dosage with tabs (with ritonavir) q12hr
Capsules can be used in patients weighing ≥33 kg
If vomiting occurs within 30 min, repeat dose
Serious - Use Alternative
Significant - Monitor Closely
Increased triglycerides (11%)
Increased serum lipase, ALT, AST (5-10%) in pts. treatment with concomitant ritonavir
Abdominal pain (≤ 2%)
Increased hepatic transaminases (4-8%)
Frequency Not Defined
Acute hemolytic anemia
Immune reconstitution syndrome
Hypersensitivity (eg, Stevens-Johnson syndrome) to fosamprenavir, amprenavir, or other component
Concomitant use of drugs that depend heavily on CYP3A4 for clearance; metabolite amprenavir is a strong CYP3A4 inhibitor; use w/ ritonavir another strong CYP3A4 inhibitor may have additive inhibitory effects; check Drug Interactions
Drugs that are contraindicated with fosamprenavir (with or without ritonavir) include alpha1-adrenoreptor agonists (eg, alfuzosin), antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, quinidine), rifampin, voriconazole, ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), cisapride, St. John’s wort, lovastatin, simvastatin, pimozide, sildenafil (when used for PAH), midazolam, and triazolam
New onset DM, exacerbation of pre-existing DM & hyperglycemia reported with unknown frequency/unknown causal relationship
Monitor labs prior to and during treatment with Hepatitis B or C, or elevated transaminases
Few reports of spontaneous bleeding in patients. with Hemophilia A and B
During initial treatment, inflammatory response to indolent or residual opportunistic infections may occur and require treatment
Fat redistribution with "cushingoid appearance" and "buffalo hump" may occur
Increased risk for myocardial infarction (thought to be caused by protease inhibitors increasing risk of hyperlipidemia)
Monitor triglycerides and cholesterol levels before initiating, then periodically; initiate clinical management of lipid disorders as required
Combination treatment with ritonavir may lead to increased triglyceride level
Unknown effect on activity of subsequently administered protease inhibitors
Risk of immune reconstitution syndrome if used in combination with other antiretroviral drugs; autoimmune disorders (eg Graves disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment
Vomiting more common in children
Cases of nephrolithiasis reported with fosamprenavir
Acute hemolytic anemia reported with amprenavir
Discontinue therapy if severe skin reactions including Stevens-Johnson syndrome occur
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excreted in milk unknown; contraindicated
Pregnancy Registry: to monitor maternal-fetal outcomes of pregnant women exposed to antiretroviral medications call 1-800-258-4263 or visit www.APRegistry.com
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Prodrug converted to amprenavir (protease inhibitor) by cellular phosphatases in vivo; 700 mg fosamprenavir equivalent to 600 mg amprenavir
Binds to active site of HIV-1 protease and thereby prevents processing of viral Gag and Gag-Pol polyprotein precursors, resulting in the formation of immature noninfectious viral particle
Half-Life: 7.7 hr
Peak Plasma Time: 1.5-4 hr
Protein Bound: 90%
Metabolism: hepatic CYP3A4
Enzymes inhibited: CYP3A4
Excretion: Feces (75%); urine (15%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs